COGT实时信号 | 通过Getagraph.com最大化利润

出售 104908 min ago

@ $8.60

发出时间: 15 Feb 2024 @ 04:09

回报率: -30.00%

上一信号: Feb 15 - 01:47

上一信号: 购买

回报率: -2.05 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	912 095
平均成交量	2.15M
市值	575.59M
EPS	$0 ( 2024-03-12 )
下一个收益日期	( $-0.500 ) 2024-05-14
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.49
ATR14	$0.00500 (0.08%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Ferrante Karen Jean	Buy	3 213	Stock Option (Right to Buy)
2024-03-28	Fairmount Funds Management Llc	Buy	286 851	Common Stock
2024-03-28	Fairmount Funds Management Llc	Buy	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	11 914	Series A Convertible Preferred Stock
2024-03-28	Fairmount Funds Management Llc	Sell	286 851	Common Stock

INSIDER POWER
88.06
Last 97 transactions
Buy: 19 542 341 \| Sell: 1 316 263

音量相关性

長: -0.11 (neutral)

短: -0.48 (neutral)

Signal:(56.59) Neutral

Cogint Inc. 相关性

10 最正相关
NWL	0.911
CPIX	0.903
PRAX	0.9
CNDT	0.891
EWTX	0.89
QMCO	0.887
AQB	0.886
AVDX	0.886
SRTS	0.885
CHB	0.885

10 最负相关
PPBT	-0.881
FIZZ	-0.864
EPZM	-0.833
SNCR	-0.822
XOG	-0.821
TYHT	-0.816
LEDS	-0.805

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Cogint Inc. 相关性 - 货币/商品

-0.17
( neutral )

-0.07
( neutral )

0.00
( neutral )

-0.44
( neutral )

Cogint Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2023
营收:	$0
毛利润:	$-3.59M (0.00 %)
EPS:	$-2.42

FY	2022
营收:	$0
毛利润:	$-5.88M (0.00 %)
EPS:	$-2.26

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-1.814

Financial Reports:

No articles found.

Cogint Inc.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.